ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in ZyVersa Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +5 vs. Q1 2023
- Shares held
- 297.1K
- +155.4K (+109.6%) vs. Q1 2023
- Total value
- $73.4K
- −$200.1K (−73.2%) vs. Q1 2023
- New holders
- 7
- 3 more added
- Sold out
- 2
- 0 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZVSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 1 | $1 |
| Q2 2025 | 6 | $44.7K |
| Q1 2025 | 7 | $43.9K |
| Q4 2024 | 8 | $86.2K |
| Q3 2024 | 6 | $7.22K |
| Q2 2024 | 4 | $38.7K |
| Q1 2024 | 8 | $84.9K |
| Q4 2023 | 6 | $181.4K |
| Q3 2023 | 12 | $161.8K |
| Q2 2023 | 11 | $73.4K |
| Q1 2023 | 6 | $273.5K |
| Q4 2022 | 2 | $123.9K |
| Q3 2022 | 29 | $73.3M |
| Q2 2022 | 25 | $62.2M |
| Q1 2022 | 21 | $55.4M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding ZyVersa Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Virtu Financial LLC | 120,377 | $30.0K | 0.00% | +120,377 | New |
| Cowen and Company, LLC | 50,000 | $12.3K | 0.00% | +50,000 | New |
| Two Sigma Securities, LLC | 39,498 | $9.70K | 0.00% | +39,498 | New |
| Cubist Systematic Strategies, LLC | 36,870 | $9.05K | 0.00% | +36,870 | New |
| Vanguard Group Inc | 17,194 | $4.22K | 0.00% | +300+1.8% | Added |
| Winthrop Advisory Group LLC | 13,361 | $3.28K | 0.00% | 00.0% | Unchanged |
| StoneX Group Inc. | 12,700 | $3.12K | 0.00% | +12,700 | New |
| Tower Research Capital LLC (TRC) | 5,746 | $1.41K | 0.00% | +1,083+23.2% | Added |
| Barclays PLC | 1,100 | $270 | 0.00% | +1,100 | New |
| Wells Fargo & Company | 109 | $27 | 0.00% | +81+289.3% | Added |
| Bank of America Corp | 100 | $24 | 0.00% | +100 | New |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −103,471−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,282−100.0% | Sold out |